Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.
Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $7.25, representing a +0.14% change from its previous close.
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Recursion Pharmaceuticals Stock a Buy?
Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (RXRX -0.31%) could be positioned to ride the ongoing wave of hype to great heights. Between its AI-first approach to designing new drugs and its positioning as a valuable collaborator for other companies, the company is worth paying attention to at a minimum.
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day.
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?
The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025?
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's pipeline and partnerships, potentially delivering up to $20 billion in milestone payments from collaborations with pharma giants. Despite unimpressive clinical trial results, the company's innovative platform and strategic partnerships justify a "Buy" rating for long-term, high-risk-tolerant investors.
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.
Is Recursion Pharmaceuticals a Millionaire-Maker Stock?
In an environment where the typical small biotech name is riskier than not, this one is curiously different.
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close.
